YM178

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Renal Impairment

Conditions

Renal Impairment

Trial Timeline

Sep 1, 2008 → Sep 1, 2009

NCT ID

NCT00750620

About YM178

YM178 is a phase 1 stage product being developed by Astellas Pharma for Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00750620. Target conditions include Renal Impairment.

What happened to similar drugs?

20 of 20 similar drugs in Renal Impairment were approved

Approved (20) Terminated (0) Active (0)

✅tacrolimus + CellCept + steroids (methylprednisone or prednisone)Astellas PharmaApproved

✅Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + PrednisoloneAstellas PharmaApproved

✅Tacrolimus, Prograf®Astellas PharmaApproved

✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus - Prograf® twice daily formulation + Tacrolimus - Advagraf® once daily formulationAstellas PharmaApproved

✅Tacrolimus + CyclosporineAstellas PharmaApproved

✅Tacrolimus sustained-release capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00337090	Phase 2	Completed	—	Mar 1, 2007	Overactive Bladder
NCT01720212	Phase 1	Completed	May 1, 2012	Aug 1, 2012	Healthy Chinese Volunteers
NCT01334905	Phase 1	Completed	Mar 1, 2011	Jun 1, 2011	Healthy Volunteer
NCT00965926	Phase 1	Completed	Jul 1, 2009	Sep 1, 2009	Healthy Volunteer
NCT00840645	Phase 3	Completed	Dec 1, 2008	Mar 1, 2010	Urinary Bladder, Overactive
NCT00750620	Phase 1	Completed	Sep 1, 2008	Sep 1, 2009	Renal Impairment

Competing Products

20 competing products in Renal Impairment

See all competitors

Product	Company	Stage	Hype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109	MBX Biosciences	Phase 1	23
LY3473329	Eli Lilly	Phase 1	29
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
Drotrecogin alfa activated (Xigris)	Eli Lilly	Phase 2	35
LY3819469	Eli Lilly	Phase 1	29
Atezolizumab + Cabozantinib	Chugai Pharmaceutical	Phase 3	32
DS-6000a + DS-6000a	Daiichi Sankyo	Phase 1	33
DS-1093a	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
AGS-16C3F	Astellas Pharma	Phase 1	29
AGS-16M8F	Astellas Pharma	Phase 1	29
CP-461	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
intravenous immunoglobulins (IVIG)	Astellas Pharma	Phase 1	29
bixalomer	Astellas Pharma	Pre-clinical	26
ASP8825	Astellas Pharma	Phase 1	29